Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2022

View Archived Issues

Medshine Discovery identifies new CREBBP and/or p300 inhibitors

Shionogi discovers 5-HT2A receptor antagonists and/or inverse agonists

New galectin-3 inhibitors synthesized at Galecto Biotech

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents G12C mutant GTPase KRAS inhibitors

IDP Discovery Pharma describes new VEGF inhibitors

M2-mAChRs as therapeutic targets for treating substance use disorders

Discovery of a new class of PDE4B inhibitors with activity in adjuvant-induced arthritis model

RAP-103 studies show potential of biphasic function opioid signaling modulators for use in analgesia

Step Pharma's CTPS1 inhibitor STP-938 cleared to enter clinic for T-cell and B-cell lymphomas

Tonix and KEMRI collaborate to advance TNX-801 as vaccine for monkeypox and smallpox

Neuron-like cells are glioblastoma's evil mastermind

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...